Skip to main content
OpenTrials
Completed

NCT Number: NCT00355953

Vascular and Skeletal Protective Effects of Genistein in Postmenopausal Women

The present research program is proposed deepening some pharmacological effects of the genistein therapy in order to individualize alternative treatments to the conventional hormonal replacement therapy useful to reduce the cardiovascular morbidity and mortality and the osteoporotic consequences in postmenopausal women.

Completed

Looking for future studies?

Notify Me

Key information

Age range

45 year–70 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2 / Phase 3

About this study

Genistein is a phytoestrogen of the isoflavone family which has been shown to have beneficial effects on endothelial function and bone metabolism. On the basis of the so far obtained results, aim of our research was to investigate for a two years period the effects of genistein on cardiovascular risk factors, endothelial function and oxidative stress markers, bone metabolism and finally clarify pathophysiology mechanisms (by dosage of cytokines and endothelial markers) by which this molecule could interfere on atherosclerosis and bone mass loss progression.

Particularly, and in extreme synthesis the following parameters have been studied during the treatment:

  • inflammation markers as fibrinogen
  • lipid profile - total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, lipoprotein(a)-
  • endothelial function markers as VCAM-1 and ICAM-1
  • oxidative stress by the evaluation of the F(2)-isoprostane
  • cytokines as IL-6, OPG, RANK and RANKL
  • bone mineral density, by DEXA, at lumbar spine and femoral neck
  • Bone turnover markers as B-ALP, PYR, D-PYR
  • PAP-test, transvaginal uterine ecography and mammography.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least one year of menopause
  • No use of hormone replacement therapy
  • Bone mineral density T-score at the femoral neck minor than one S.D.

Exclusion criteria

  • Concomitant disease
  • Smoke habit

Treatment and study plan

Genistein

Drug

Primary outcomes

  1. Efficacy:

  2. bone resorption/formation

  3. bone mineral density

  4. cardiovascular risk factors

  5. Safety:

  6. endometrial thickness

Secondary outcomes

  1. Efficacy:

  2. hot flushes reduction

  3. Safety:

  4. mammography

  5. vaginal cells maturation value

Sponsors and collaborators

Lead sponsor

University of Messina

Other

Registry information

Important dates

Study start
2003
Study completion
2005
First posted
Jul 25, 2006
Registry last updated
Apr 22, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.